Signal active
Organization
Contact Information
Overview
Juvena Therapeutics is a venture-backed biopharma startup discovering novel protein-based therapeutics that promote tissue regeneration in the elderly and treat various age-related diseases.
About
Biotechnology, Health Care, Biopharma
2017
11-50
Headquarters locations
Palo Alto, California, United States, North America
Social
Profile Resume
Juvena Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Biopharma sector. The company focuses on Biotechnology and has secured $3.5B in funding across 72 round(s). With a team of 11-50 employees, Juvena Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Juvena Therapeutics, raised $41.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
6
13
0
$49.2M
Details
3
Juvena Therapeutics has raised a total of $49.2M in funding over 3 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2018 | Seed | 4.3M | ||
2020 | Seed | |||
2022 | Early Stage Venture | 41.0M |
Investors
Juvena Therapeutics is funded by 26 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Plum Alley | - | FUNDING ROUND - Plum Alley | 41.0M |
Intersect VC | - | FUNDING ROUND - Intersect VC | 41.0M |
Juvena Therapeutics | - | FUNDING ROUND - Juvena Therapeutics | 41.0M |
Irongrey | - | FUNDING ROUND - Irongrey | 41.0M |
Recent Activity
News
May 29, 2024
LinkedIn - Hanadie Yousef on LinkedIn: I'll be at BIO 2024 - join me!
News
May 05, 2024
LinkedIn - Kyuho Han on LinkedIn: Pharos iBio and MEDiC to collaborate on new drug research
News
Apr 23, 2024
LinkedIn - Kyuho Han on LinkedIn: Pharos iBio and MEDiC to collaborate on new drug research
News
Apr 04, 2024
LinkedIn - Juvena Therapeutics on LinkedIn: Our CEO, Dr. Hanadie Yousef had a wonderful time at our major investor and…
News
Mar 14, 2024
The Business Journals - How Juvena Therapeutics' CEO found inspiration from family in her fight against chronic illnesses - San Francisco ...
News
Feb 01, 2024
Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy ...